Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

universities

- PMLiVE

SMC: Celgene’s Abraxane ‘too expensive’ for Scotland

But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta

- PMLiVE

ASCO: AstraZeneca shows off cancer immunotherapy

MEDI4736 could rival Merck & Co’s anti-PD1 inhibitor pembrolizumab

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

US cancer ads come under fire

Study concludes that cancer advertisements tug at the heartstrings without providing sufficient information

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

GSK and Bayer strike new biotech cancer deals

Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

Celgene leadership changes spark succession speculation

Movement at biotech includes promotions for Mark Alles and Jacqualyn Fouse

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Macmillan campaign for legacy donations

Cancer charity aims to raise awareness of the importance of gifts in wills

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links